S.B. NO. <sup>1274</sup> S.D. 2 H.D. 3

C.D. 1

# A BILL FOR AN ACT

RELATING TO HEALTH INSURANCE.

#### BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

1 SECTION 1. The legislature finds that the purpose of this 2 Act is to comply with the requirements of the Patient Protection 3 and Affordable Care Act of 2010, Public Law No. 111-148, and its 4 implementing regulations by updating Hawaii's Patients' Bill of 5 Rights and Responsibilities Act, chapter 432E, Hawaii Revised 6 Statutes, to conform to the requirements of the federal law. 7 SECTION 2. Chapter 432E, Hawaii Revised Statutes, is 8 amended by adding a new part to be appropriately designated and 9 to read as follows: 10 "PART EXTERNAL REVIEW OF HEALTH 11 INSURANCE DETERMINATIONS 12 §432E-A Applicability and scope. (a) Except as provided in subsection (b), this part shall apply to all health carriers. 13 This part shall not apply to a policy or certificate 14 (b) 15 that provides coverage only for a specified disease, specified 16 accident or accident-only coverage, credit, dental, disability 17 income, hospital indemnity, long-term care insurance, vision 18 care, or any other limited supplemental benefit; to a medicare 2011-2273 SB1274 CD1 SMA-3.doc 

#### **S.B. NO.** <sup>1274</sup> S.D. 2 H.D. 3 C.D. 1

supplemental policy of insurance, coverage under a plan through 1 2 medicare, medicaid, or the federal employees health benefits 3 program, any federal medical and dental care coverage issued 4 under chapter 55 of Title 10 United States Code and any coverage issued as supplemental to that coverage; any coverage issued as 5 supplemental to liability insurance, workers' compensation, or 6 7 similar insurance; automobile medical-payment insurance; any 8 insurance under which benefits are payable with or without 9 regard to fault, whether written on a group blanket or 10 individual basis; or the employer union health benefits trust 11 fund so long as it is self-funded.

12 §432E-B Notice of right to external review. Notice of the 13 right to external review issued pursuant to this part shall set 14 forth the options available to the enrollee under this part. 15 The commissioner may specify the form and content of notice of 16 external review.

17 §432E-C Request for external review. (a) All requests
18 for external review of a health carrier's adverse action shall
19 be made in writing to the commissioner and shall include:

20 (1) A copy of the final internal determination of the
21 health carrier, unless exempted pursuant to subsection
22 (b);



S.B. NO. <sup>1274</sup> S.D. 2 H.D. 3 C.D. 1

1 (2) A signed authorization by or on behalf of the enrollee 2 for release of the enrollee's medical records relevant 3 to the external review; 4 (3) A disclosure for conflict of interests evaluation, as 5 provided in section 432E-M; and A filing fee of \$15, which shall be deposited into the 6 (4)7 compliance resolution fund established pursuant to 8 section 26-9(0); provided that the filing fee shall be 9 refunded if the adverse determination or final 10 internal adverse determination is reversed through 11 external review. 12 The commissioner shall waive the filing fee required by this subsection if the commissioner determines that payment of the 13 14 fee would impose an undue financial hardship to the enrollee. The annual aggregate limit on filing fees for any enrollee 15 16 within a single plan year shall not exceed \$60. 17 (b) The internal appeals process of a health carrier shall

18 be completed before an external review request shall be 19 submitted to the commissioner except in the following 20 circumstances:

21 (1) The health carrier has waived the requirement of
22 exhaustion of the internal appeals process;





(2) The enrollee has applied for an expedited external
 review at the same time that the enrollee applied for
 an expedited internal appeal; provided that the
 enrollee is eligible for an expedited external review;
 or

6 (3) The health carrier has substantially failed to comply
7 with its internal appeals process.

8 §432E-D Standard external review. (a) An enrollee or the 9 enrollee's appointed representative may file a request for an 10 external review with the commissioner within one hundred thirty 11 days of receipt of notice of an adverse action. Within three 12 business days after the receipt of a request for external review 13 pursuant to this section, the commissioner shall send a copy of 14 the request to the health carrier.

(b) Within five business days following the date of receipt of the copy of the external review request from the commissioner pursuant to subsection (a), the health carrier shall determine whether:

19 (1) The individual is or was an enrollee in the health
20 benefit plan at the time the health care service was
21 requested or, in the case of a retrospective review,



**S.B. NO.** <sup>1274</sup> s.d. 2 H.D. 3 C.D. 1

5

1 was an enrollee in the health benefit plan at the time 2 the health care service was provided; 3 (2) The health care service that is the subject of the 4 adverse determination or the final adverse 5 determination would be a covered service under the 6 enrollee's health benefit plan but for a determination 7 by the health carrier that the health care service 8 does not meet the health carrier's requirements for 9 medical necessity, appropriateness, health care 10 setting, level of care, or effectiveness; 11 (3) The enrollee has exhausted the health carrier's 12 internal appeals process or the enrollee is not 13 required to exhaust the health carrier's internal 14 appeals process pursuant to section 432E-C(b); and 15 The enrollee has provided all the information and (4)16 forms required to process an external review, 17 including a completed release form and disclosure form as required by section 432E-C(a). 18 19 (c)Within three business days after a determination of an 20 enrollee's eligibility for external review pursuant to subsection (b), the health carrier shall notify the 21 commissioner, the enrollee, and the enrollee's appointed 22 2011-2273 SB1274 CD1 SMA-3.doc 

#### S.B. NO. <sup>1274</sup> S.D. 2 H.D. 3 C.D. 1

representative in writing as to whether the request is complete
 and whether the enrollee is eligible for external review.

If the request for external review submitted pursuant to this section is not complete, the health carrier shall inform the commissioner, the enrollee, and the enrollee's appointed representative in writing that the request is incomplete and shall specify the information or materials required to complete the request.

9 If the enrollee is not eligible for external review
10 pursuant to subsection (b), the health carrier shall inform the
11 commissioner, the enrollee, and the enrollee's appointed
12 representative in writing that the enrollee is not eligible for
13 external review and the reasons for ineligibility.

Notice of ineligibility for external review pursuant to this section shall include a statement informing the enrollee and the enrollee's appointed representative that a health carrier's initial determination that the external review request is ineligible for review may be appealed to the commissioner by submission of a request to the commissioner.

20 (d) Upon receipt of a request for appeal pursuant to
21 subsection (c), the commissioner shall review the request for
22 external review submitted by the enrollee pursuant to subsection



1

2

3

4

5

6

7

8

9

(a), determine whether an enrollee is eligible for external review and, if eligible, shall refer the enrollee to external review. The commissioner's determination of eligibility for external review shall be made in accordance with the terms of the enrollee's health benefit plan and all applicable provisions of this part. If an enrollee is not eligible for external review, the commissioner shall notify the enrollee, the enrollee's appointed representative, and the health carrier within three business days of the reason for ineligibility.

1274 S.D. 2

S.B. NO.

10 (e) When the commissioner receives notice pursuant to
11 subsection (c) or makes a determination pursuant to subsection
12 (d) that an enrollee is eligible for external review, within
13 three business days after receipt of the notice or determination
14 of eligibility, the commissioner shall:

15 (1) Randomly assign an independent review organization 16 from the list of approved independent review 17 organizations qualified to conduct the external 18 review, based on the nature of the health care service 19 that is the subject of the adverse action and other 20 factors determined by the commissioner including 21 conflicts of interest pursuant to section 432E-M, 22 compiled and maintained by the commissioner to conduct

#### **S.B. NO.** <sup>1274</sup> S.D. 2 H.D. 3 C.D. 1

a

1	the external review and notify the health carrier of
2	the name of the assigned independent review
3	organization; and
4	(2) Notify the enrollee and the enrollee's appointed
5	representative, in writing, of the enrollee's
6	eligibility and acceptance for external review.
7	(f) An enrollee or an enrollee's appointed representative
8	may submit additional information in writing to the assigned
9	independent review organization for consideration in its
10	external review. The independent review organization shall
11	consider information submitted within five business days
12	following the date of the enrollee's receipt of the notice
13	provided pursuant to subsection (e). The independent review
14	organization may accept and consider additional information
15	submitted by an enrollee or an enrollee's appointed
16	representative after five business days.
17	(g) Within five business days after the date of receipt of
18	notice pursuant to subsection (e), the health carrier or its
19	designated utilization review organization shall provide to the
20	assigned independent review organization all documents and
21	information it considered in issuing the adverse action that is
22	the subject of external review. Failure by the health carrier





1 or its utilization review organization to provide the documents 2 and information within five business days shall not delay the 3 conduct of the external review; provided that the assigned 4 independent review organization may terminate the external 5 review and reverse the adverse action that is the subject of the 6 external review. The independent review organization shall 7 notify the enrollee, the enrollee's appointed representative. the health carrier, and the commissioner within three business 8 9 days of the termination of an external review and reversal of an 10 adverse action pursuant to this subsection.

11 (h) The assigned independent review organization shall, within one business day of receipt by the independent review 12 organization, forward all information received from the enrollee 13 14 pursuant to subsection (f) to the health carrier. Upon receipt 15 of information forwarded to it pursuant to this subsection, a 16 health carrier may reconsider the adverse action that is the 17 subject of the external review; provided that reconsideration by 18 the health carrier shall not delay or terminate an external 19 review unless the health carrier reverses its adverse action and 20 provides coverage or payment for the health care service that is 21 the subject of the adverse action. The health carrier shall 22 notify the enrollee, the enrollee's appointed representative,



1


2

3

4

5

6



7 the health carrier.

8 (i) In addition to the documents and information provided pursuant to subsections (f) and (g), the assigned independent 9 10 review organization shall consider the following in reaching a 11 decision:

12 (1)The enrollee's medical records;

13 (2) The attending health care professional's

14 recommendation;


15 (3) Consulting reports from appropriate health care 16 professionals and other documents submitted by the 17 health carrier, enrollee, enrollee's appointed 18 representatives, or enrollee's treating provider;

- 19 (4) The application of medical necessity as defined in 20 section 432E-1;
- 21 (5) The most appropriate practice guidelines, which shall 22 include applicable evidence-based standards and may

2011-2273 SB1274 CD1 SMA-3.doc



16



1		include any practice guidelines developed by the
2		federal government or national or professional medical
3		societies, boards, and associations;
4	(6)	Any applicable clinical review criteria developed and
5		used by the health carrier or its designated
6		utilization review organization; and
7	(7)	The opinion of the independent review organization's
8		clinical reviewer or reviewers pertaining to the
9		information enumerated in paragraphs (1) through (5)
10		to the extent the information or documents are
11		available and the clinical reviewer or reviewers
12		consider appropriate.
13	In r	eaching a decision, the assigned independent review
14	organizat	ion shall not be bound by any decisions or conclusions
15	reached d	uring the health carrier's utilization review or
	_	

17 organization's decision shall not contradict the terms of the 18 enrollee's health benefit plan or this part.

internal appeals process; provided that the independent review

S.B. NO. <sup>1274</sup> S.D. 2 H.D. 3 C.D. 1

12

1 commissioner of its decision to uphold or reverse the adverse 2 action that is the subject of the internal review. The 3 independent review organization shall include in the notice of 4 its decision: 5 A general description of the reason for the request (1) 6 for external review; 7 (2) The date the independent review organization received 8 the assignment from the commissioner to conduct the 9 external review; 10 (3)The date the external review was conducted; 11 (4)The date the decision was issued; and 12 (5) The basis for the independent review organization's 13 decision, including its reasoning, rationale, and the 14 supporting evidence or documentation, including 15 evidence-based standards, that the independent review 16 organization considered in reaching its decision. 17 Upon receipt of a notice of a decision reversing the adverse action, the health carrier shall immediately approve the 18 19 coverage that was the subject of the adverse action. **\$432E-E Expedited external review.** (a) Except as 20


provided in subsection (i), an enrollee or the enrollee's

2011-2273 SB1274 CD1 SMA-3.doc



1	appointed	representative may request an expedited external
2	review wi	th the commissioner if the enrollee receives:
3	(1)	An adverse determination that involves a medical
4		condition of the enrollee for which the timeframe for
5		completion of an expedited internal appeal would
6		seriously jeopardize the enrollee's life, health, or
7		ability to gain maximum functioning or would subject
8		the enrollee to severe pain that cannot be adequately
9	ţ	managed without the care or treatment that is the
10		subject of the adverse determination;
11	(2)	A final adverse determination if the enrollee has a
12		medical condition where the timeframe for completion
13		of a standard external review would seriously
14		jeopardize the enrollee's ability to gain maximum
15		functioning, or would subject the enrollee to severe
16		pain that cannot be adequately managed without the
17		care or treatment that is the subject of the adverse
18		determination; or
19	(3)	A final adverse determination if the final adverse
20		determination concerns an admission, availability of
21		care, continued stay, or health care service for which
22		the enrollee received emergency services; provided

2011-2273 SB1274 CD1 SMA-3.doc



14

1 that the enrollee has not been discharged from a
2 facility for health care services related to the
3 emergency services.

4 Upon receipt of a request for an expedited external (b) 5 review, the commissioner shall immediately send a copy of the 6 request to the health carrier. Immediately upon receipt of the 7 request, the health carrier shall determine whether the request meets the reviewability requirements set forth in subsection 8 9 The health carrier shall immediately notify the enrollee (a). 10 or the enrollee's appointed representative of its determination 11 of the enrollee's eligibility for expedited external review. Notice of ineligibility for expedited external review shall 12 13 include a statement informing the enrollee and the enrollee's 14 appointed representative that a health carrier's initial 15 determination that an external review request that is ineligible 16 for review may be appealed to the commissioner by submission of

17 a request to the commissioner.

(c) Upon receipt of a request for appeal pursuant to
subsection (b), the commissioner shall review the request for
expedited external review submitted pursuant to subsection (a)
and, if eligible, shall refer the enrollee for external review.
The commissioner's determination of eligibility for expedited
2011-2273 SB1274 CD1 SMA-3.doc

1 external review shall be made in accordance with the terms of 2 the enrollee's health benefit plan and all applicable provisions 3 of this part. If an enrollee is not eligible for expedited 4 external review, the commissioner shall immediately notify the 5 enrollee, the enrollee's appointed representative, and the 6 health carrier of the reasons for ineligibility.

1274 S.D. 2

S.B. NO.

7 (d) If the commissioner determines that an enrollee is eligible for expedited external review even though the enrollee 8 9 has not exhausted the health carrier's internal review process, 10 the health carrier shall not be required to proceed with its 11 internal review process. The health carrier may elect to proceed with its internal review process even though the request 12 13 is determined by the commissioner to be eligible for expedited 14 external review; provided that the internal review process shall 15 not delay or terminate an expedited external review unless the 16 health carrier decides to reverse its adverse determination and 17 provide coverage or payment for the health care service that is 18 the subject of the adverse determination. Immediately after 19 making a decision to reverse its adverse determination, the 20 health carrier shall notify the enrollee, the enrollee's 21 authorized representative, the independent review organization 22 assigned pursuant to subsection (c), and the commissioner in the 2011-2273 SB1274 CD1 SMA-3.doc 15 

Page 16

writing of its decision. The assigned independent review
 organization shall terminate the expedited external review upon
 receipt of notice from the health carrier pursuant to this
 subsection.

1274 S.D. 2

16

S.B. NO.


5 (e) Upon receipt of the notice pursuant to subsection (a) 6 or a determination of the commissioner pursuant to subsection 7 (c) that the enrollee meets the eligibility requirements for 8 expedited external review, the commissioner shall immediately 9 randomly assign an independent review organization to conduct 10 the expedited external review from the list of approved 11 independent review organizations qualified to conduct the 12 external review, based on the nature of the health care service 13 that is the subject of the adverse action and other factors 14 determined by the commissioner including conflicts of interest 15 pursuant to section 432E-M, compiled and maintained by the 16 commissioner to conduct the external review and immediately 17 notify the health carrier of the name of the assigned 18 independent review organization.

19 (f) Upon receipt of the notice from the commissioner of 20 the name of the independent review organization assigned to 21 conduct the expedited external review, the health carrier or its 22 designee utilization review organization shall provide or



17

transmit all documents and information it considered in making 1 2 the adverse action that is the subject of the expedited external 3 review to the assigned independent review organization 4 electronically or by telephone, facsimile, or any other 5 available expeditious method. 6 In addition to the documents and information provided (q) 7 or transmitted pursuant to subsection (f), the assigned independent review organization shall consider the following in 8 9 reaching a decision: 10 The enrollee's pertinent medical records; (1)11 (2)The attending health care professional's 12 recommendation; 13 (3) Consulting reports from appropriate health care 14 professionals and other documents submitted by the 15 health carrier, enrollee, the enrollee's appointed representative, or the enrollee's treating provider; 16 17 The application of medical necessity criteria as (4) 18 defined in section 432E-1; 19 (5) The most appropriate practice guidelines, which shall 20 include evidence-based standards, and may include any 21 other practice guidelines developed by the federal




18

vernment, national or professional medical
cieties, boards, and associations;
y applicable clinical review criteria developed and
ed by the health carrier or its designee utilization
view organization in making adverse determinations;
d
e opinion of the independent review organization's
inical reviewer or reviewers pertaining to the
formation enumerated in paragraphs (1) through (5)
the extent the information and documents are
ailable and the clinical reviewer or reviewers
nsider appropriate.
hing a decision, the assigned independent review
shall not be bound by any decisions or conclusions
ng the health carrier's utilization review or
eals process; provided that the independent review
's decision shall not contradict the terms of the
ealth benefit plan or this part.
expeditiously as the enrollee's medical condition

or circumstances requires, but in no event more than seventy-two 21 hours after the date of receipt of the request for an expedited external review that meets the reviewability requirements set 22

2011-2273 SB1274 CD1 SMA-3.doc 



S.B. NO. <sup>1274</sup> S.D. 2 H.D. 3 C.D. 1

20

1 external review with the commissioner within one hundred thirty
2 days of receipt of notice of an adverse action that involves a
3 denial of coverage based on a determination that the health care
4 service or treatment recommended or requested is experimental or
5 investigational.

6 (b) An enrollee or the enrollee's appointed representative 7 may make an oral request for an expedited external review of the adverse action if the enrollee's treating physician certifies, 8 9 in writing, that the health care service or treatment that is 10 the subject of the request would be significantly less effective 11 if not promptly initiated. A written request for an expedited 12 external review pursuant to this subsection shall include, and 13 oral request shall be promptly followed by, a certification 14 signed by the enrollee's treating physician and the 15 authorization for release and disclosures required by section 16 432E-C. Upon receipt of all items required by this subsection, 17 the commissioner shall immediately notify the health carrier. 18 (c) Upon notice of the request for expedited external 19 review, the health carrier shall immediately determine whether 20 the request meets the requirements of subsection (b). The 21 health carrier shall immediately notify the commissioner, the

enrollee, and the enrollee's appointed representative of its
 eligibility determination.

1274 S.D. 2

23

S.B. NO.

Notice of eligibility for expedited external review
pursuant to this subsection shall include a statement informing
the enrollee and, if applicable, the enrollee's appointed
representative that a health carrier's initial determination
that the external review request is ineligible for review may be
appealed to the commissioner.

9 Upon receipt of a request for appeal pursuant to (d) 10 subsection (c), the commissioner shall review the request for 11 external review submitted by the enrollee pursuant to subsection 12 (a), determine whether an enrollee is eligible for external 13 review and, if eligible, shall refer the enrollee to external 14 review. The commissioner's determination of eligibility for 15 external review shall be made in accordance with the terms of 16 the enrollee's health benefit plan and all applicable provisions 17 of this part. If an enrollee is not eliqible for external 18 review, the commissioner shall notify the enrollee, the 19 enrollee's appointed representative, and the health carrier of 20 the reason for ineligibility within three business days.

(e) Upon receipt of the notice pursuant to subsection (a)
or a determination of the commissioner pursuant to subsection



S.B. NO. CD1

22

1 (d) that the enrollee meets the eligibility requirements for 2 expedited external review, the commissioner shall immediately randomly assign an independent review organization to conduct 3 4 the expedited external review from the list of approved 5 independent review organizations qualified to conduct the 6 external review, based on the nature of the health care service 7 that is the subject of the adverse action and other factors 8 determined by the commissioner including conflicts of interest 9 pursuant to section 432E-M, compiled and maintained by the 10 commissioner to conduct the external review and immediately 11 notify the health carrier of the name of the assigned 12 independent review organization.

Upon receipt of the notice from the commissioner of 13 (f)the name of the independent review organization assigned to 14 15 conduct the expedited external review, the health carrier or its 16 designee utilization review organization shall provide or 17 transmit all documents and information it considered in making 18 the adverse action that is the subject of the expedited external 19 review to the assigned independent review organization 20 electronically or by telephone, facsimile, or any other 21 available expeditious method.




#### S.B. NO. <sup>1274</sup> S.D. 2 H.D. 3 C.D. 1

**Z**3

1 (g) Except for a request for an expedited external review 2 made pursuant to subsection (b), within three business days 3 after the date of receipt of the request, the commissioner shall notify the health carrier that the enrollee has requested an 4 5 expedited external review pursuant to this section. Within five business days following the date of receipt of notice, the 6 7 health carrier shall determine whether: 8 The individual is or was an enrollee in the health (1)9 benefit plan at the time the health care service or 10 treatment was recommended or requested or, in the case 11 of a retrospective review, was an enrollee in the 12 health benefit plan at the time the health care 13 service or treatment was provided; 14 (2) The recommended or requested health care service or 15 treatment that is the subject of the adverse action: 16 (A) Would be a covered benefit under the enrollee's 17 health benefit plan but for the health carrier's 18 determination that the service or treatment is 19 experimental or investigational for the 20 enrollee's particular medical condition; and 21 (B) Is not explicitly listed as an excluded benefit 22 under the enrollee's health benefit plan;

2011-2273 SB1274 CD1 SMA-3.doc



1	(3)	The	enrollee's treating physician has certified in
2		writ	ing that:
3		(A)	Standard health care services or treatments have
4			not been effective in improving the condition of
5			the enrollee;
6		(B)	Standard health care services or treatments are
7			not medically appropriate for the enrollee; or
8		(C)	There is no available standard health care
9			service or treatment covered by the health
10			carrier that is more beneficial than the health
11			care service or treatment that is the subject of
12			the adverse action;
13	(4)	The	enrollee's treating physician:
14		(A)	Has recommended a health care service or
15			treatment that the physician certifies, in
16			writing, is likely to be more beneficial to the
17			enrollee, in the physician's opinion, than any
18			available standard health care services or
19			treatments; or
20		(B)	Who is a licensed, board certified or board
21			eligible physician qualified to practice in the
22			area of medicine appropriate to treat the



S.B. NO. <sup>1274</sup> S.D. 2 H.D. 3 C.D. 1

25

1 enrollee's condition, has certified in writing 2 that scientifically valid studies using accepted 3 protocols demonstrate that the health care 4 service or treatment that is the subject of the 5 adverse action is likely to be more beneficial to 6 the enrollee than any available standard health 7 care services or treatments;

The enrollee has exhausted the health carrier's 8 (5) 9 internal appeals process or the enrollee is not 10 required to exhaust the health carrier's internal appeals process pursuant to section 432E-C(b); and 11 12 The enrollee has provided all the information and (6) 13 forms required by the commissioner that are necessary 14 to process an external review, including the release 15 form and disclosure of conflict of interest 16 information as provided under section 432E-5. 17 Within three business days after determining the (h) 18 enrollee's eligibility for external review pursuant to 19 subsection (g), the health carrier shall notify the 20 commissioner, the enrollee, and the enrollee's appointed 21 representative in writing as to whether the request is complete

22 and eligible for external review.

#### S.B. NO. <sup>1274</sup> S.D. 2 H.D. 3 C.D. 1

If the request is not complete, the health carrier shall
 inform the commissioner, the enrollee, and the enrollee's
 appointed representative in writing of the information or
 materials needed to complete the request.

5 If the enrollee is not eligible for external review 6 pursuant to subsection (g), the health carrier shall inform the 7 commissioner, the enrollee, and the enrollee's appointed 8 representative in writing of the ineligibility and the reasons 9 for ineligibility.

Notice of ineligibility pursuant to this subsection shall
include a statement informing the enrollee and the enrollee's
appointed representative that a health carrier's initial
determination that the external review request is ineligible for
review may be appealed to the commissioner by submitting a
request to the commissioner.

16 If a request for external review is determined eligible for 17 external review, the health carrier shall notify the 18 commissioner and the enrollee and, if applicable, the enrollee's 19 appointed representative.

20 (i) Upon receipt of a request for appeal pursuant to
21 subsection (h), the commissioner shall review the request for
22 external review submitted pursuant to subsection (a) and, if

## 2011-2273 SB1274 CD1 SMA-3.doc

S.B. NO. <sup>1274</sup> S.D. 2 H.D. 3 C.D. 1

27

eligible, shall refer the enrollee for external review. 1 The 2 commissioner's determination of eligibility for expedited 3 external review shall be made in accordance with the terms of 4 the enrollee's health benefit plan and all applicable provisions 5 of this part. If an enrollee is not eligible for external 6 review, the commissioner shall notify the enrollee, the 7 enrollee's appointed representative, and the health carrier of the reasons for ineligibility within three business days. 8 9 When the commissioner receives notice pursuant to (i) subsection (h) or makes a determination pursuant to subsection 10 11 (i) that an enrollee is eligible for external review, within 12 three business days after receipt of the notice or determination 13 of eligibility, the commissioner shall: 14 (1) Randomly assign an independent review organization 15 from the list of approved independent review 16 organizations qualified to conduct the external · 17 review, based on the nature of the health care service 18 that is the subject of the adverse action and other

factors determined by the commissioner including conflicts of interest pursuant to section 432E-M,

21 compiled and maintained by the commissioner pursuant
22 to conduct the external review and notify the health

2011-2273 SB1274 CD1 SMA-3.doc

19

**S.B. NO.** <sup>1274</sup> s.d. 2 H.D. 3 C.D. 1

28

1 carrier of the name of the assigned independent review 2 organization; and

3 (2) Notify the enrollee and the enrollee's appointed
4 representative, in writing, of the enrollee's
5 eligibility and acceptance for external review.

6 An enrollee or an enrollee's appointed representative (k) 7 may submit additional information in writing to the assigned 8 independent review organization for consideration in its 9 external review. The independent review organization shall 10 consider information submitted within five business days 11 following the date of the enrollee's receipt of the notice 12 provided pursuant to subsection (j). The independent review 13 organization may accept and consider additional information submitted by an enrollee after five business days. 14

15 (1)Within five business days after the date of receipt of notice pursuant to subsection (j), the health carrier or its 16 17 designated utilization review organization shall provide to the 18 assigned independent review organization all documents and 19 information it considered in issuing the adverse action that is 20 the subject of external review. Failure by the health carrier 21 or its utilization review organization to provide the documents 22 and information within five business days shall not delay the

2011-2273 SB1274 CD1 SMA-3.doc



29

1 conduct of the external review; provided that the assigned 2 independent review organization may terminate the external 3 review and reverse the adverse action that is the subject of the 4 external review. The independent review organization shall 5 notify the enrollee, the enrollee's appointed representative, 6 the health carrier, and the commissioner within three business 7 days of the termination of an external review and reversal of an 8 adverse action pursuant to this subsection.

9 (m) Within three business days after the receipt of the 10 notice of assignment to conduct the external review pursuant to 11 subsection (j), the assigned independent review organization 12 shall:

13 (1)Select one or more clinical reviewers who each shall 14 be a physician or other health care professional who 15 meets the minimum qualifications described in section 16 432E-I and, through clinical experience in the past 17 three years, is an expert in the treatment of the 18 enrollee's condition and knowledgeable about the 19 recommended or requested health care service or 20 treatment to conduct the external review; provided 21 that neither the enrollee, the enrollee's appointed 22 representative, nor the health carrier shall choose or



#### S.B. NO. <sup>1274</sup> S.D. 2 H.D. 3 C.D. 1

30

control the choice of the physicians or other health 1 2 care professionals to be selected to conduct the 3 external review; and 4 Based on the written opinion of the clinical reviewer, (2) 5 or opinions if more than one clinical reviewer has 6 been selected, to the assigned independent review 7 organization on whether the recommended or requested 8 health care service or treatment should be covered, 9 make a determination to uphold or reverse the adverse 10 action. 11 In reaching an opinion, the clinical reviewers are not

11 In reaching an opinion, the clinical reviewers are not
12 bound by any decisions or conclusions reached during the health
13 carrier's utilization review process or internal appeals
14 process.

Each clinical reviewer selected pursuant to this subsection shall review all of the information and documents received pursuant to subsection (1) and any other information submitted in writing by the enrollee or the enrollee's authorized representative pursuant to this subsection.

20 (n) The assigned independent review organization, within
21 one business day of receipt by the independent review
22 organization, shall forward all information received from the
2011-2273 SB1274 CD1 SMA-3.doc

S.B. NO. <sup>1274</sup> S.D. 2 H.D. 3 C.D. 1

31

enrollee pursuant to subsection (k) to the health carrier. 1 Upon 2 receipt of information forwarded to it pursuant to this subsection, a health carrier may reconsider the adverse action 3 4 that is the subject of the external review; provided that 5 reconsideration by the health carrier shall not delay or 6 terminate an external review unless the health carrier reverses 7 its adverse action and provides coverage or payment for the 8 health care service that is the subject of the adverse action. 9 The health carrier shall notify the enrollee, the enrollee's 10 appointed representative, the assigned independent review 11 organization, and the commissioner in writing of its decision to 12 reverse its adverse action and within three business days of 13 making its decision to reverse the adverse action and provide 14 coverage. The assigned independent review organization shall terminate its external review upon receipt of notice pursuant to 15 16 this subsection from the health carrier.

(o) Except as provided in subsection (p), within twenty days after being selected to conduct the external review, a clinical reviewer shall provide an opinion to the assigned independent review organization pursuant to subsection (q) regarding whether the recommended or requested health care


1 service or treatment subject to an appeal pursuant to this 2 section shall be covered. 3 The clinical reviewers' opinion shall be in writing and shall include: 4 5 (1)A description of the enrollee's medical condition; 6 (2) A description of the indicators relevant to 7 determining whether there is sufficient evidence to demonstrate that the recommended or requested health 8 9 care service or treatment is more likely than not to 10 be more beneficial to the enrollee than any available 11 standard health care services or treatments and 12 whether the adverse risks of the recommended or 13 requested health care service or treatment would not be substantially increased over those of available 14 15 standard health care services or treatments: 16 (3) A description and analysis of any medical or scientific evidence, as that term is defined in 17 18 section 432E-1.4, considered in reaching the opinion; 19 (4) A description and analysis of any medical necessity 20 criteria defined in section 432E-1; and

1274 S.D. 2

32

S.B. NO.

21 (5) Information on whether the reviewer's rationale for
22 the opinion is based on approval of the health care




33

1 service or treatment by the federal Food and Drug 2 Administration for the condition or medical or 3 scientific evidence or evidence-based standards that 4 demonstrate that the expected benefits of the 5 recommended or requested health care service or 6 treatment is likely to be more beneficial to the 7 enrollee than any available standard health care 8 services or treatments and the adverse risks of the 9 recommended or requested health care service or 10 treatment would not be substantially increased over 11 those of available standard health care services or 12 treatments.

(p) Notwithstanding the requirements of subsection (o), in an expedited external review, the clinical reviewer shall provide an opinion orally or in writing to the assigned independent review organization as expeditiously as the enrollee's medical condition or circumstances require, but in no event more than five calendar days after being selected in accordance with subsection (m).

20 If the opinion provided pursuant to this subsection was not 21 in writing, within forty-eight hours following the date the 22 opinion was provided, the clinical reviewer shall provide

2011-2273 SB1274 CD1 SMA-3.doc



1274 S.D. 2

34

**S.B. NO.** <sup>1274</sup> S.D. 2 H.D. 3 C.D. 1

35

1 of the recommended or requested health care 2 service or treatment is more likely than not to 3 be beneficial to the enrollee than any available 4 standard health care service or treatment and the 5 adverse risks of the recommended or requested 6 health care service or treatment would not be 7 substantially increased over those of available 8 standard health care services or treatments; 9 provided that the independent review organization's decision 10 shall not contradict the terms of the enrollee's health benefit

11 plan or the provisions of this chapter.

12 (r) Except as provided in subsection (s), within twenty 13 days after the date it receives the opinion of the clinical 14 reviewer pursuant to subsection (o), the assigned independent 15 review organization, in accordance with subsection (t), shall 16 determine whether the health care service at issue in an 17 external review pursuant to this section shall be a covered 18 benefit and shall notify the enrollee, the enrollee's appointed 19 representative, the health carrier, and the commissioner of its 20 determination. The independent review organization shall 21 include in the notice of its decision:

### S.B. NO. <sup>1274</sup> S.D. 2 H.D. 3 C.D. 1

1	(1)	A general description of the reason for the request
2		for external review;
3	(2)	The written opinion of each clinical reviewer,
4		including the recommendation of each clinical reviewer
5		as to whether the recommended or requested health care
6		service or treatment should be covered and the
7		rationale for the reviewer's recommendation;
8	(Ĩ)	The date the independent review organization was
9		assigned by the commissioner to conduct the external
10		reviewer;
11	(4)	The date the external review was conducted;
12	(5)	The date the decision was issued;
13	(6)	The principal reason or reasons for its decision; and
14	(7)	The rationale for its decision.
15	Upon	receipt of a notice of a decision reversing the
16	adverse ad	ction, the health carrier immediately shall approve
17	coverage d	of the recommended or requested health care service or
18	treatment	that was the subject of the adverse action.
19	(s)	For an expedited external review, within forty-eight
20	hours afte	er the date it receives the opinion of each clinical
21	reviewer,	the assigned independent review organization, in
22	accordance	e with subsection (t), shall make a decision and
	THE MARK CARD THREE MARK THE MARKE METER THREE THREE IN	SB1274 CD1 SMA-3.doc

#### S.B. NO. <sup>1274</sup> S.D. 2 H.D. 3 C.D. 1

provide notice of the decision orally or in writing to the
 enrollee, the enrollee's appointed representative, the health
 carrier, and the commissioner.

If the notice provided was not in writing, within fortyeight hours after the date of providing that notice, the assigned independent review organization shall provide written confirmation of the decision to the enrollee, the enrollee's appointed representative, the health carrier, and the commissioner.

10 (t) If a majority of the clinical reviewers recommends 11 that the recommended or requested health care service or 12 treatment should be covered, the independent review organization 13 shall make a decision to reverse the health carrier's adverse 14 determination or final adverse determination.

15 If a majority of the clinical reviewers recommends that the 16 recommended or requested health care service or treatment should 17 not be covered, the independent review organization shall make a 18 decision to uphold the health carrier's adverse determination or 19 final adverse determination.

20 If the clinical reviewers are evenly split as to whether 21 the recommended or requested health care service or treatment 22 should be covered, the independent review organization shall

### 2011-2273 SB1274 CD1 SMA-3.doc

1 obtain the opinion of an additional clinical reviewer in order 2 for the independent review organization to make a decision based 3 on the opinions of a majority of the clinical reviewers. The 4 additional clinical reviewer shall use the same information to 5 reach an opinion as the clinical reviewers who have already 6 submitted their opinions. The selection of the additional 7 clinical reviewer shall not extend the time within which the 8 assigned independent review organization is required to make a 9 decision based on the opinions of the clinical reviewers 10 selected.

1274 S.D. 2

38

S.B. NO.

11 §432E-G Binding nature of external review decision. (a)
12 An external review decision shall be binding on the health
13 carrier and the enrollee except to the extent that the health
14 carrier or the enrollee has other remedies available under
15 applicable federal or state law.

(b) An enrollee or the enrollee's appointed representative shall not file a subsequent request for external review involving the same adverse action for which the enrollee has already received an external review decision pursuant to this part.

\$432E-H Approval of independent review organizations. (a)
 An independent review organization shall be approved by the 2011-2273 SB1274 CD1 SMA-3.doc

	Page 39	<b>S.B. NO.</b> <sup>1274</sup> S.D. 2 H.D. 3 C.D. 1
1	commissio	oner in order to be eligible to be assigned to conduct
2	external	reviews under this part.
3	(b)	To be eligible for approval by the commissioner to
4	conduct e	external reviews under this part an independent review
5	organizat	ion shall:
6	(1)	Submit an application on a form required by the
7		commissioner and include all documentation and
8		information necessary for the commissioner to
9		determine if the independent review organization
10		satisfies the minimum qualifications established under
11		this part; and
12	(2)	Except as otherwise provided in subsection (c), shall
13		be accredited by a nationally-recognized private
14		accrediting entity that the commissioner has
15		determined has independent review organization
16		accreditation standards that are equivalent to or
17		exceed the minimum standards established by this
18		section and section 432E-I.
19	(c)	The commissioner may approve independent review
20	_	ions that are not accredited by a nationally-recognized
21	private a	ccrediting entity if there are no acceptable

### 2011-2273 SB1274 CD1 SMA-3.doc



40

nationally-recognized private accrediting entities providing
 independent review organization accreditation.

3 (d) The commissioner may charge an application fee that
4 the independent review organizations shall submit to the
5 commissioner with an application for approval and re-approval.

6 (e) Approval pursuant to this section is effective for two 7 years, unless the commissioner determines before its expiration 8 that the independent review organization does not meet the 9 minimum qualifications established under this part. If the commissioner determines that an independent review organization 10 has lost its accreditation or no longer satisfies the minimum 11 12 requirements of this part, the commissioner shall terminate the 13 approval of the independent review organization and remove the 14 independent review organization from the list of independent review organizations approved to conduct external reviews 15 16 maintained by the commissioner.

17 (f) The commissioner shall maintain and periodically18 update a list of approved independent review organizations.

19 §432E-I Minimum qualifications for independent review
20 organizations. (a) To be eligible for approval under this part
21 to conduct external reviews, an independent review organization
22 shall have and maintain written policies and procedures that



18

19

1274 S.D. 2 S.B. NO. C.D. 1

1 govern all aspects of both the standard external review process and the expedited external review process set forth in this part 2 3 that include, at minimum:

4	(1)	A qua	ality assurance mechanism in place that ensures:
5		(A)、	That external reviews are conducted within the
6			specified time frames of this part and required
7			notices are provided in a timely manner;
8		(B)	The selection of qualified and impartial clinical
9			reviewers to conduct external reviews on behalf
10			of the independent review organization and
11			suitable matching of reviewers to specific cases;
12			provided that an independent review organization
13			shall employ or contract with an adequate number
14			of clinical reviewers to meet this objective;
15		(C)	Confidentiality of medical and treatment records
16			and clinical review criteria; and
17		(D)	That any person employed by or under contract

with the independent review organization complies with the requirements of this part;


20 (2) Toll-free telephone, facsimile, and email capabilities 21 to receive information related to external reviews 22 twenty-four hours a day, seven days per week that are

2011-2273 SB1274 CD1 SMA-3.doc 

### **S.B. NO.** <sup>1274</sup> S.D. 2 H.D. 3 C.D. 1

42

1		capable of accepting, recording, or providing
2		appropriate instruction to incoming telephone callers
3		during other than normal business hours and
4		facilitating necessary communication under this part;
5		and
6	(3)	An agreement to maintain and provide to the
7		commissioner the information required by this part.
8	(b)	Each clinical reviewer assigned by an independent
9	review or	ganization to conduct an external review shall be a
10	physician	or other appropriate health care provider who:
11	(1)	Is an expert in the treatment of the medical condition
12		that is the subject of the external review;
13	(2)	Is knowledgeable about the recommended health care
14		service and treatment through recent or current actual
15		clinical experience treating patients with the same or
16		similar medical condition at issue in the external
17		review;
18	(3)	Holds a non-restricted license in a state of the
19		United States and, for physicians, a current
20		certification by a recognized American Medical
21		Specialty Board in the area or areas appropriate to
22		the subject of the external review; and




(4) Has no history of disciplinary actions or sanctions,
 including loss of staff privileges or participation
 restrictions, imposed or pending by any hospital,
 governmental agency or unit, or regulatory body that
 raises a substantial question as to the clinical
 reviewer's physical, mental, or professional
 competence or moral character.

8 (c) An independent review organization shall not own or 9 control, be a subsidiary of, or in any way be owned or 10 controlled by, or exercise control over a health carrier, health 11 benefit plan, a national, state, or local trade association of 12 health benefit plans, or a national, state, or local trade 13 association of health care providers.

(d) To be eligible to conduct an external review of a specified case, neither the independent review organization selected to conduct the external review nor any clinical reviewer assigned by the independent review organization to conduct the external review shall have a material professional, familial, or financial conflict of interest with any of the following:


21 (1) The health carrier that is the subject of the external
22 review;





.

1	(2)	The enrollee whose treatment is the subject of the
2		external review, the enrollee's appointed
3		representative, or the enrollee's immediate family;
4	(3)	Any officer, director, or management employee of the
5		health carrier that is the subject of the external
6		review;
7	(4)	The health care provider, the health care provider's
8		medical group, or independent practice association
9		recommending the health care service or treatment that
10		is the subject of the external review;
11	(5)	The facility at which the recommended health care
12		service or treatment would be provided;
13	(6)	The developer or manufacturer of the principal drug,
14		device, procedure, or other therapy recommended for
15		the enrollee whose treatment is the subject of the
16		external review; or
17	(7)	The health benefit plan that is the subject of the
18		external review, the plan administrator, or any
19		fiduciary or employee of the plan.
20	The o	commissioner may determine that no material
21	profession	nal, familial, or financial conflict of interest exists
22	based on t	the specific characteristics of a particular
	a superior contra Petri Di dina dal bitar Mattina (1816 1191) ILANS DI	SB1274 CD1 SMA-3.doc "



45


1 relationship or connection that creates an apparent 2 professional, familial, or financial conflict of interest. 3 (e) An independent review organization that is accredited 4 by a nationally-recognized private accrediting entity that has 5 independent review accreditation standards that the commissioner 6 has determined are equivalent to or exceed the minimum 7 qualifications of this section shall be presumed to be in 8 compliance with this section to be eligible for approval under 9 this part. 10 The commissioner shall review, initially upon approval of 11 an accredited independent review organization and periodically 12 during the time that the independent review organization remains 13 approved pursuant to this section, the accreditation standards 14 of the nationally-recognized private accrediting entity to determine whether the entity's standards are, and continue to be 15 16

17 under this section; provided that a review conducted by the National Association of Insurance Commissioners shall satisfy 18 19 the requirements of this section.

equivalent to, or exceed the minimum qualifications established

20 Upon request of the commissioner, a nationally-recognized 21 private accrediting entity shall make its current independent review organization accreditation standards available to the 22 2011-2273 SB1274 CD1 SMA-3.doc 

10



46

1 commissioner or the National Association of Insurance 2 Commissioners in order for the commissioner to determine if the entity's standards are equivalent to or exceed the minimum 3 4 qualifications established under this section. The commissioner 5 may exclude any private accrediting entity that is not reviewed 6 by the National Association of Insurance Commissioners.

7 (f) An independent review organization shall establish and maintain written procedures to ensure that it is unbiased in 8 9 addition to any other procedures required under this section.

§432E-J Hold harmless for independent review organizations. No independent review organization or clinical 11 reviewer working on behalf of an independent review organization 12 or an employee, agent, or contractor of an independent review 13 14 organization shall be liable in damages to any person for any 15 opinions rendered or acts or omissions performed within the 16 scope of the organization's or person's duties under the law 17 during or upon completion of an external review conducted 18 pursuant to this part, unless the opinion was rendered or the 19 act or omission was performed in bad faith or involved gross 20 negligence.

21 \$432E-K External review reporting requirements. (a) An 22 independent review organization assigned pursuant to this part 2011-2273 SB1274 CD1 SMA-3.doc 

1 to conduct an external review shall maintain written records in 2 the aggregate by state and by health carrier on all requests for 3 external review for which it conducted an external review during 4 a calendar year and upon request shall submit a report to the 5 commissioner, as required under subsection (b).

(b) Each independent review organization required to
maintain written records on all requests for external review
pursuant to subsection (a) for which it was assigned to conduct
an external review shall submit to the commissioner, upon
request, a report in the format specified by the commissioner.
The report shall include in the aggregate by state, and for each
health carrier:

13 (1) The total number of requests for external review;
14 (2) The number of requests for external review resolved
15 and, of those resolved, the number resolved upholding
16 the adverse action and the number resolved reversing
17 the adverse action;

18 (3) The average length of time for resolution;

19 (4) The summary of the types of coverages or cases for
20 which an external review was sought, as provided in
21 the format required by the commissioner;



47

1274 S.D. 2

C.D. 1


S.B. NO.

#### S.B. NO. <sup>1274</sup> S.D. 2 H.D. 3 C.D. 1

1 (5) The number of external reviews that were terminated as 2 the result of a reconsideration by the health carrier 3 of its adverse action after the receipt of additional 4 information from the enrollee or the enrollee's 5 appointed representative; and 6 Any other information the commissioner may request or (6) 7 require. The independent review organization shall retain the 8 written records required pursuant to this subsection for at 9 10 least three years. 11 Each health carrier shall maintain written records in (c) the aggregate, by state and for each type of health benefit plan 12 13 offered by the health carrier on all requests for external 14 review that the health carrier receives notice of from the 15 commissioner pursuant to this part. 16 Each health carrier required to maintain written records on 17 all requests for external review shall submit to the 18 commissioner, upon request, a report in the format specified by the commissioner that includes in the aggregate, by state, and 19 20 by type of health benefit plan:

21

The total number of requests for external review;




49

(2) From the total number of requests for external review
 reported, the number of requests determined eligible
 for a full external review; and

4 (3) Any other information the commissioner may request or
5 require.

6 The health carrier shall retain the written records required pursuant to this subsection for at least three years. 7 §432E-L Funding of external review. The health carrier 8 9 against which a request for a standard external review or an 10 expedited external review is filed shall pay the cost of the independent review organization for conducting the external 11 12 There shall be no recourse against the commissioner for review. 13 the cost of conducting the external review and the selection of 14 an independent review organization shall not be subject to 15 chapter 103D; provided that the commissioner may initially 16 approve up to three independent review organizations to serve 17 beginning on the effective date of this part until the initial 18 procurement process is completed; provided further that in any 19 year in which procurement subject to chapter 103D does not 20 produce at least three independent review organizations eligible 21 for selection under section 432E-I, the commissioner may approve



50

up to three independent review organizations notwithstanding the
 requirements of chapter 103D.

3 §432E-M Disclosure requirements. (a) Each health carrier
4 shall include a description of the external review procedures in
5 or attached to the policy, certificate, membership booklet,
6 outline of coverage, or other evidence of coverage it provides
7 to enrollees.

8 (b) Disclosure shall be in a format prescribed by the 9 commissioner and shall include a statement informing the 10 enrollee of the right of the enrollee to file a request for an 11 external review of an adverse action with the commissioner. The 12 statement may explain that external review is available when the 13 adverse action involves an issue of medical necessity, 14 appropriateness, health care setting, level of care, or 15 effectiveness. The statement shall include the telephone number 16 and address of the commissioner.

(c) In addition to the requirements of subsection (b), the statement shall inform the enrollee that, when filing a request for an external review, the enrollee or the enrollee's appointed representative shall be required to authorize the release of any medical records of the enrollee that may be required to be reviewed for the purpose of reaching a decision on the external

2011-2273 SB1274 CD1 SMA-3.doc



51

review and shall be required to provide written disclosures to
 permit the commissioner to perform a conflict of interest
 evaluation for selection of an appropriate independent review
 organization.

5 (d) Each health carrier shall have available on its 6 website and provide upon request to any enrollee, forms for the 7 purpose of requesting an external review, which shall include an 8 authorization release form that complies with the federal Health 9 Insurance Portability and Accountability Act as well as a 10 disclosure form for conflict of interest evaluation purposes 11 that shall include the name of the enrollee, any authorized 12 representative acting on behalf of the enrollee, the enrollee's 13 immediate family members, the health carrier that is the subject 14 of the external review, the health benefit plan, the plan administrator, plan fiduciaries and plan employees if the 15 16 enrollee is in a group health benefits plan, the health care 17 providers treating the enrollee for purposes of the condition 18 that is the subject of the external review and the providers' 19 medical groups, the health care provider and facility at which 20 the requested health care service or treatment would be 21 provided, and the developer or manufacturer of the principal

1

2

drug, device, procedure, or other therapy that is the subject of the external review request.

1274 S.D. 2

52

S.B. NO.

3 (e) Each health carrier doing business in Hawaii shall 4 file with the commissioner by the effective date of this part, 5 information to permit the commissioner to perform a conflict of 6 interest evaluation for selection of an appropriate independent 7 review organization in the event of a request for external review involving the health carrier. A filing pursuant to this 8 9 section shall include the name of the health carrier, its 10 officers, directors, and management employees. The health 11 carrier shall promptly amend its filing with the commissioner when there is any change of officers, directors, or managing 12 13 employees.

(f) The commissioner may prescribe the form or format to
use for the release authorization required by subsection (d) and
the conflict of interest disclosures required by subsections (d)
and (e).

(g) No disclosure required for purposes of this part shall
include lawyer-client privileged communications protected
pursuant to the Hawaii Rules of Evidence Rule 503.

21 §432E-N Rules. The insurance commissioner shall adopt
22 rules pursuant to chapter 91 to effectuate the purpose of this

### S.B. NO. <sup>1274</sup> S.D. 2 H.D. 3 C.D. 1

1	part including requirements for forms to request external review
2	and expedited external review, to request approval by
3	independent review organizations, and for disclosure of
4	conflicts of interest by enrollees and health carriers."
5	SECTION 3. Chapter 432E, Hawaii Revised Statutes, is
6	amended by designating sections 432E-1 through 432E-2 as part I,
7	entitled "General Provisions".
8	SECTION 4. Chapter 432E, Hawaii Revised Statutes, is
9	amended by designating sections 432E-3 through 432E-8 as part
10	II, entitled "General Policies".
11	SECTION 5. Chapter 432E, Hawaii Revised Statutes, is
12	amended by designating sections 432E-9 through 432E-13 as part
13	III, entitled "Reporting and Other Provisions".
14	SECTION 6. Section 432E-1, Hawaii Revised Statutes, is
15	amended to read as follows:
16	<b>"§432E-1 Definitions.</b> As used in this chapter, unless the
17	context otherwise requires:
18	"Adverse action" means an adverse determination or a final
19	adverse determination.
20	"Adverse determination" means a determination by a health
21	carrier or its designated utilization review organization that
22	an admission, availability of care, continued stay, or other
	2011-2273 SB1274 CD1 SMA-3.doc

### **S.B. NO.** <sup>1274</sup> S.D. 2 H.D. 3 C.D. 1

54

1	health care service that is a covered benefit has been reviewed
2	and, based upon the information provided, does not meet the
3	health carrier's requirements for medical necessity,
4	appropriateness, health care setting, level of care, or
5	effectiveness, and the requested service or payment for the
6	service is therefore denied, reduced, or terminated.
7	"Ambulatory review" means a utilization review of health
8	care services performed or provided in an outpatient setting.
9	"Appeal" means a request from an enrollee to change a
10	previous decision made by the [managed care plan.] health
11	carrier.
12	"Appointed representative" means a person who is expressly
13	permitted by the enrollee or who has the power under Hawaii law
14	to make health care decisions on behalf of the enrollee,
15	including:
16	(1) A person to whom an enrollee has given express written
17	consent to represent the enrollee in an external
18	review;
19	(2) A person authorized by law to provide substituted
20	consent for an enrollee;

1


### 1274 S.D. 2 H.D. 3 C.D. 1 S.B. NO.

1	(3)	A family member of the enrollee or the enrollee's
2		treating health care professional, only when the
3		enrollee is unable to provide consent;
4	[ <del>(1)</del> ]	(4) A court-appointed legal guardian;
5	[ <del>(2)</del> ]	(5) A person who has a durable power of attorney for
6		health care; or
7	[ <del>-(3)</del> ]	(6) A person who is designated in a written advance
8		directive[-];
9	provided	that an appointed representative shall include an
10	"authorize	ed representative" as used in the federal Patient
11	Protection	n and Affordable Care Act.
12	"Best	t evidence" means evidence based on:
13	(1)	Randomized clinical trials;
14	(2)	If randomized clinical trials are not available,
15		cohort studies or case-control studies;
16	(3)	If the trials in paragraphs (1) and (2) are not
17		available, case-series; or
18	(4)	If the sources of information in paragraphs (1), (2),
19		and (3) are not available, expert opinion.
20	"Case	e management" means a coordinated set of activities
21	conducted	for individual patient management of serious,
22	complicate	ed, protracted, or other health conditions.

1274 S.D. 2 H.D. 3 C.D. 1 S.B. NO.


1	"Case-control study" means a prospective evaluation of two
2	groups of patients with different outcomes to determine which
3	specific interventions the patients received.
4	"Case-series" means an evaluation of patients with a
5	particular outcome, without the use of a control group.
6	"Certification" means a determination by a health carrier
7	or its designated utilization review organization that an
8	admission, availability of care, continued stay, or other health
9	care service has been reviewed and, based on the information
10	provided, satisfies the health carrier's requirements for
11	medical necessity, appropriateness, health care setting, level
12	of care, and effectiveness.
13	"Clinical review criteria" means the written screening
14	procedures, decision abstracts, clinical protocols, and practice
15	guidelines used by a health carrier to determine the necessity
16	and appropriateness of health care services.
17	"Cohort study" means a prospective evaluation of two groups
18	of patients with only one group of patients receiving a specific
19	intervention.
20	"Commissioner" means the insurance commissioner.
21	"Complaint" means an expression of dissatisfaction, either
22	oral or written.







٠

1	"Concurrent review" means a utilization review conducted
2	during a patient's hospital stay or course of treatment.
3	"Covered benefits" or "benefits" means those health care
4	services to which an enrollee is entitled under the terms of a
5	health benefit plan.
6	"Discharge planning" means the formal process for
7	determining, prior to discharge from a facility, the
8	coordination and management of the care that an enrollee
9	receives following discharge from a facility.
10	"Disclose" means to release, transfer, or otherwise divulge
11	protected health information to any person other than the
12	individual who is the subject of the protected health
13	information.
14	"Emergency services" means services provided to an enrollee
15	when the enrollee has symptoms of sufficient severity that a
16	layperson could reasonably expect, in the absence of medical
17	treatment, to result in placing the enrollee's health or
18	condition in serious jeopardy, serious impairment of bodily
19	functions, serious dysfunction of any bodily organ or part, or
20	death.



1	"Enrollee" means a person who enters into a contractual
2	relationship under or who is provided with health care services
3	or benefits through a [managed care plan.] health benefit plan.
4	["Expedited appeal" means the internal review of a
5	complaint-or-an external review of the final internal
6	determination of an enrollee's complaint, which is completed
7	within seventy two hours after receipt of the request for
8	expedited appeal.
9	"External review" means an administrative review requested
10	by an enrollee under section 432E-6 of a managed care-plan's
11	final internal determination of an enrollee's complaint.]
12	"Evidence-based standard" means the conscientious,
13	explicit, and judicious use of the current best evidence based
14	on the overall systematic review of the research in making
15	decisions about the care of individual patients.
16	"Expert opinion" means a belief or interpretation by
17	specialists with experience in a specific area about the
18	scientific evidence pertaining to a particular service,
19	intervention, or therapy.
20	"External review" means a review of an adverse
21	determination (including a final adverse determination)





,

59

1	conducted by an independent review organization pursuant to this
2	chapter.
3	"Facility" means an institution providing health care
4	services or a health care setting, including but not limited to,
5	hospitals and other licensed inpatient centers, ambulatory
6	surgical or treatment centers, skilled nursing centers,
7	residential treatment centers, diagnostic, laboratory and
8	imaging centers, and rehabilitation and other therapeutic health
9	settings.
10	"Final adverse determination" means an adverse
11	determination involving a covered benefit that has been upheld
12	by a health carrier or its designated utilization review
13	organization at the completion of the health carrier's internal
14	grievance process procedures, or an adverse determination with
15	respect to which the internal appeals process is deemed to have
16	been exhausted under section 432E-C(b).
17	"Health benefit plan" means a policy, contract, certificate
18	or agreement offered or issued by a health carrier to provide,
19	deliver, arrange for, pay or reimburse any of the costs of
20	health care services.
21	"Health care [ <del>provider"</del> ] professional" means an individual
22	licensed, accredited, or certified to provide or perform

1	specified health care services in the ordinary course of
2	business or practice of a profession[-] consistent with state
3	law.
4	"Health care provider" or "provider" means a health care
5	professional.
6	"Health care services" means services for the diagnosis,
7	prevention, treatment, cure, or relief of a health condition,
8	illness, injury, or disease.
9	"Health carrier" means an entity subject to the insurance
10	laws and rules of this State, or subject to the jurisdiction of
11	the commissioner, that contracts or offers to contract to
12	provide, deliver, arrange for, pay for, or reimburse any of the
13	costs of health care services, including a sickness and accident
14	insurance company, a health maintenance organization, a mutual
15	benefit society, a nonprofit hospital and health service
16	corporation, or any other entity providing a plan of health
17	insurance, health benefits or health care services.
18	"Health maintenance organization" means a health
19	maintenance organization as defined in section 432D-1.
20	"Independent review organization" means an independent
21	entity [that:
22	(1) Is-unbiased and able to make independent decisions;




60

1274 S.D. 2 H.D. 3 C.D. 1

S.B. NO.

### **S.B. NO.** <sup>1274</sup> S.D. 2 H.D. 3 C.D. 1

1	- <del>(2)</del>	Engages adequate numbers of practitioners with the
2		appropriate level and type of clinical knowledge and
3		expertise;
4	<del>(3)</del>	Applies evidence-based decisionmaking;
5	<del>(4)</del>	Demonstrates an effective process to screen external
6		reviews for eligibility;
7	- <del>(5)</del>	Protects the enrollee's identity from unnecessary
8		disclosure; and
9	<del>(6)</del>	Has effective systems in place to conduct a review.]
10	that condu	acts independent external reviews of adverse
11	determinat	tions and final adverse determinations.
12	"Inte	ernal review" means the review under section 432E-5 of
13	an enrolle	ee's complaint by a [managed care-plan.] health
14	carrier.	
15	"Mana	aged care plan" means any plan, policy, contract,
16	certificat	e, or agreement, regardless of form, offered or
17	administer	red by any person or entity, including but not limited
18	to an insu	arer governed by chapter 431, a mutual benefit society
19	governed b	by chapter 432, a health maintenance organization
20	governed b	y chapter 432D, a preferred provider organization, a
21	point of s	service organization, a health insurance issuer, a
22	fiscal int	ermediary, a payor, a prepaid health care plan, and
	I TACINE INTEL COLUMN INTEL INTEL COLUMN INTEL COLUMN	SB1274 CD1 SMA-3.doc



62

1 any other mixed model, that provides for the financing or 2 delivery of health care services or benefits to enrollees 3 through: 4 (1)Arrangements with selected providers or provider 5 networks to furnish health care services or benefits; 6 and 7 Financial incentives for enrollees to use (2) 8 participating providers and procedures provided by a 9 plan; 10 provided [-7] that for the purposes of this chapter, an employee 11 benefit plan shall not be deemed a managed care plan with 12 respect to any provision of this chapter or to any requirement 13 or rule imposed or permitted by this chapter [which] that is 14 superseded or preempted by federal law. 15 "Medical director" means the person who is authorized under 16 a [managed\_care\_plan] health carrier and who makes decisions for 17 the [plan] health carrier denying or allowing payment for 18 medical treatments, services, or supplies based on medical 19 necessity or other appropriate medical or health plan benefit 20 standards.

21 "Medical necessity" means a health intervention [as
22 defined] that meets the criteria enumerated in section 432E-1.4.
2011-2273 SB1274 CD1 SMA-3.doc

,

	Page 63	S.B. NO. <sup>1274</sup> S.D. 2 H.D. 3
		C.D. 1
1	"Med	lical or scientific evidence" means evidence found in
2		wing sources:
3	(1)	Peer-reviewed scientific studies published in or
4		accepted for publication by medical journals that meet
5		nationally-recognized requirements for scientific
6		manuscripts and that submit most of their published
7		articles for review by experts, who are not part of
8		the editorial staff;
9	(2)	Peer-reviewed medical literature, including literature
10		relating to therapies reviewed and approved by a
11		qualified institutional review board, biomedical
12		compendia, and other medical literature that meet the
13		criteria of the National Institutes of Health's
14		National Library of Medicine for indexing in Index
15		Medicus and Elsevier Science Ltd. for indexing in
16		Excerpta Medicas;
17	(3)	Medical journals recognized by the United States
18		Secretary of Health and Human Services under Section
19		1861(t)(2) of the federal Social Security Act;
20	(4)	The following standard reference compendia:
21		(A) The American Hospital Formulary Service-Drug
22		Information;

63

·

.

#### **S.B. NO.** <sup>1274</sup> S.D. 2 H.D. 3 C.D. 1


•

1		(B) Drug Facts and Comparisons;
2		(C) The American Dental Association Accepted Dental
3		Therapeutics; and
4		(D) The United States Pharmacopeia Drug Information;
5	(5)	Findings, studies, or research conducted by or under
6		the auspices of federal government agencies and
7		nationally-recognized federal research institutes,
8		including:
9		(A) The federal Agency for Healthcare Research and
10		Quality;
11 ·		(B) The National Institutes of Health;
12		(C) The National Cancer Institute;
13		(D) The National Academy of Sciences;
14		(E) The Centers for Medicare and Medicaid Services;
15		(F) The federal Food and Drug Administration; and
16		(G) Any national board recognized by the National
17		Institutes of Health for the purpose of
18		evaluating the medical value of health care
19		services; or
20	(6)	Any other medical or scientific evidence that is
21		comparable to the sources listed in paragraphs (1)
22		through (5).



`

.



1	"Participating provider" means a licensed or certified
2	provider of health care services or benefits, including mental
3	health services and health care supplies, [ <del>that</del> ] who has entered
4	into an agreement with a [ <del>managed care plan</del> ] <u>health carrier</u> to
5	provide those services or supplies to enrollees.
6	"Prospective review" means utilization review conducted
7	prior to an admission or a course of treatment.
8	"Protected health information" means health information as
9	defined in the federal Health Insurance Portability and
10	Accountability Act and related federal rules.
11	"Randomized clinical trial" means a controlled, prospective
12	study of patients who have been randomized into an experimental
13	group and a control group at the beginning of the study with
14	only the experimental group of patients receiving a specific
15	intervention, which includes study of the groups for variables
16	and anticipated outcomes over time.
17	"Retrospective review" means a review of medical necessity
18	conducted after services that have been provided to a patient,
19	but does not include the review of a claim that is limited to an
20	evaluation of reimbursement levels, veracity of documentation,
21	accuracy of coding, or adjudication for payment.

2011-2273 SB1274 CD1 SMA-3.doc

### S.B. NO. <sup>1274</sup> S.D. 2 H.D. 3 C.D. 1

1	"Reviewer" means an independent reviewer with clinical
2	expertise either employed by or contracted by an independent
3	review organization to perform external reviews.
4	"Second opinion" means an opportunity or requirement to
5	obtain a clinical evaluation by a provider other than the one
6	originally making a recommendation for a proposed health care
7	service to assess the clinical necessity and appropriateness of
8	the initial proposed health care service.
9	"Specifically excluded" means that the coverage provisions
10	of the health care plan, when read together, clearly and
11	specifically exclude coverage for a health care service.
12	"Utilization review" means a set of formal techniques
13	designed to monitor the use of, or evaluate the clinical
14	necessity, appropriateness, efficacy, or efficiency of, health
15	care services, procedures, or settings. Techniques may include
16	ambulatory review, prospective review, second opinion,
17	certification, concurrent review, case management, discharge
18	planning, or retrospective review.
19	"Utilization review organization" means an entity that
20	conducts utilization review other than a health carrier
21	performing a review for its own health benefit plans."





SECTION 7. Section 432E-5, Hawaii Revised Statutes, is
 amended to read as follows:
 "\$432E-5 Complaints and appeals procedure for enrollees.
 (a) A [managed care plan] health carrier with enrollees in this
 State shall establish and maintain a procedure to provide for

1274 S.D. 2

C.D. 1

S.B. NO.

6 the resolution of an enrollee's complaints and <u>internal</u> appeals. 7 The procedure shall provide for expedited <u>internal</u> appeals under 8 section 432E-6.5. The definition of medical necessity in 9 section 432E-1.4 shall apply in a [managed care plan's] <u>health</u> 10 <u>carrier's</u> complaints and <u>internal</u> appeals procedures.

11 (b) The [managed care plan] health carrier shall at all times make available its complaints and internal appeals 12 procedures. The complaints and internal appeals procedures 13 shall be reasonably understandable to the average layperson and 14 shall be provided in a language other than English upon request. 15 (c) A [managed care plan] health carrier shall decide any 16 expedited internal appeal as soon as possible after receipt of 17 the complaint, taking into account the medical exigencies of the 18 case, but not later than seventy-two hours after receipt of the 19 20 request for expedited appeal.

(d) A [managed care plan] <u>health carrier</u> shall send notice of its final internal determination within sixty days of the 2011-2273 SB1274 CD1 SMA-3.doc

submission of the complaint to the enrollee, the enrollee's 1 appointed representative, if applicable, the enrollee's treating 2 provider, and the commissioner. The notice shall include the 3 following information regarding the enrollee's rights and 4 5 procedures: The enrollee's right to request an external review; 6 (1)The [sixty-day] one hundred thirty day deadline for 7 (2)8 requesting an external review; 9 Instructions on how to request an external review; and (3) 10 Where to submit the request for an external review. (4) In addition to these general requirements, the notice shall 11 12 conform to the requirements of section 432E-E." SECTION 8. Section 432E-6.5, Hawaii Revised Statutes, is 13 amended by amending its title to read as follows: 14 "§432E-6.5 Expedited internal appeal, when authorized; 15 16 standard for decision." SECTION 9. Section 432E-6.5, Hawaii Revised Statutes, is 17 amended by amending subsection (a) to read as follows: 18 "(a) An enrollee may request that the [following] internal 19 appeal under section 432E-5 be conducted as an expedited 20 21 [appeal: 22 (1) The internal review-under section 432E-5 of the

1274 S.D. 2

C.D. 1

68

S.B. NO.

### **S.B. NO.** <sup>1274</sup> S.D. 2 H.D. 3 C.D. 1

69

-1	enrollee s complaint; or
2	<del>(2)</del> The external review under section 432E-6 of the
3	managed-care plan's final-internal-determination.]
4	appeal.
5	If a request for expedited appeal is approved by the [ <del>managed</del>
6	care plan or the commissioner,] health carrier, the appropriate
7	[review] internal appeal shall be completed within seventy-two
8	hours of receipt of the request for expedited appeal."
9	SECTION 10. Section 432E-6, Hawaii Revised Statutes, is
10	repealed.
11	["§432E-6 External review procedure. (a) After
12	exhausting all internal complaint and appeal procedures
13	available, an enrollee, or the enrollee's treating provider or
14	appointed representative, may file a request for external review
15	of a managed care plan's final internal determination to a
16	three member review panel appointed by the commissioner composed
17	of a representative from a managed care plan not involved in the
18	complaint, a provider licensed to practice and practicing
19	medicine in Hawaii not involved in the complaint, and the
20	commissioner or the commissioner's designce in the following
21	manner:

### **S.B. NO.** <sup>1274</sup> S.D. 2 H.D. 3 C.D. 1

70

1	<del>(1)</del>	The enrollee shall submit a request for external
2		review to the commissioner within sixty days from the
3		date of the final internal determination by the
4		managed-care-plan;
5	<del>(2)</del>	The commissioner may retain:
6		(A) Without regard to chapter 76, an independent
7		medical expert trained in the field of medicine
8		most appropriately related to the matter under
9		review. Presentation of evidence for this
10		purpose shall be exempt from section 91 9(g); and
11		(B) The services of an independent review
12		organization from an approved list maintained by
13		the commissioner;
14	<del>(3)</del>	Within seven days after receipt of the request for
15		external-review, a-managed care plan or-its-designee
16		utilization review organization shall provide to the
17		commissioner or the assigned independent review
18		organization:
19		(A) Any documents or information-used in making-the
20		final internal determination including the
21		enrollee's medical records;

### S.B. NO. <sup>1274</sup> S.D. 2 H.D. 3 C.D. 1

1	- <del>(B)</del>	Any documentation or written information
2		submitted to the managed care plan in support of
3		the enrollee's initial complaint; and
4	<del>(C)</del>	A list of the names, addresses, and telephone
5		numbers of each licensed health care provider who
6		cared for the enrollee and who may have medical
7		records relevant to the external review;
8	provi	ded that where an expedited appeal is involved,
9	the m	anaged care plan or its designce utilization
10	revie	w organization-shall-provide the documents-and
11	infor	mation-within-forty-eight hours of receipt of the
12	reque	<del>st for external review.</del>
12 13		<del>st for external review.</del> <del>Failure by the managed care plan or its designee</del>
13	utili	Failure by-the managed-care-plan or its-designee
13 14	<del>utili</del> docum	Failure by-the-managed-care-plan or its-designee zation review organization-to provide the
13 14 15	utili docum perio	Failure by-the-managed-care-plan or its-designee zation review organization-to provide the ents and information within the prescribed-time
13 14 15 16	utili docum perio revie	Failure by-the managed care plan or its designee zation review organization to provide the ents and information within the prescribed time ds shall not delay the conduct of the external
13 14 15 16 17	utili docum perio revie revie	Failure by-the managed care plan or its designee zation review organization to provide the ents and information within the prescribed time ds shall not delay the conduct of the external w Where the plan or its designee utilization
13 14 15 16 17 18	utili docum <del>perio</del> <del>revie</del> <del>revie</del> infor	Failure by-the managed care plan or its designee zation review organization to provide the ents and information within the prescribed time ds shall not delay the conduct of the external w. Where the plan or its designee utilization w organization fails to provide the documents and
<ol> <li>13</li> <li>14</li> <li>15</li> <li>16</li> <li>17</li> <li>18</li> <li>19</li> </ol>	utili docum perio revie revie infor commi	Failure by-the managed care plan or its designee zation review organization to provide the ents and information within the prescribed time ds shall not delay the conduct of the external w. Where the plan or its designee utilization w organization fails to provide the documents and mation within the prescribed time periods, the
<ol> <li>13</li> <li>14</li> <li>15</li> <li>16</li> <li>17</li> <li>18</li> <li>19</li> <li>20</li> </ol>	utili docum perio revie revie infor commi- interi	Failure by the managed care plan or its designee zation review organization to provide the ents and information within the prescribed time ds shall not delay the conduct of the external w. Where the plan or its designee utilization w organization fails to provide the documents and mation within the prescribed time periods, the ssioner may issue a decision to reverse the final



### **S.B. NO.** <sup>1274</sup> S.D. 2 H.D. 3 C.D. 1

1		the enrollee, the enrollee's appointed representative,
2		if applicable, the enrollee's treating provider, and
3		the managed care plan of the decision;
4	-(4-)-	Upon receipt of the request for external review and
5		upon a showing of good cause, the commissioner shall
6		appoint the members of the external review panel and
7		shall conduct a review hearing pursuant to chapter 91.
8		<del>If the amount in controversy is less than \$500, the</del>
9		commissioner may conduct a review hearing without
10		appointing-a review-panel;
11	-(5)	The review hearing shall be conducted as soon as
12		practicable, taking into consideration the medical
13		exigencies of the case; provided that:
14		(A) The hearing shall-be held no later than sixty
15		days from the date of the request for the
16		hearing; and
17		(B) An external review conducted as an expedited
18		appeal shall be determined no later than seventy
19		two hours after receipt of the request-for
20		<del>external review;</del>
21	<del>.(6)</del>	After considering the enrollee's complaint, the
22		managed care plan's response, and any affidavits filed
	2011-2273	SB1274 CD1 SMA-2 dog



### **S.B. NO.** <sup>1274</sup> S.D. 2 H.D. 3 C.D. 1

1		<del>by t</del>	he parties, the commissioner may dismiss the
2		requ	est for external review if it is determined that
3		the-	request is frivolous or without merit; and
4	<del>-(7-)-</del>	<del>The-</del>	review panel shall-review every final internal
5		dete	rmination to determine whether the managed care
6		<del>plan</del>	involved acted reasonably. The review panel and
7		the-	commissioner or the commissioner's designee shall
8		cons	<del>ider:</del>
9		<del>(A)</del> -	The terms of the agreement of the enrollee's
10			insurance policy, evidence of coverage, or
11			similar document;
12	-	<del>(B)</del> -	Whether the medical director properly applied the
13			medical necessity criteria in section 432E-1.4 in
14			making the final-internal determination;
15	-	<del>(C)</del>	A <del>ll relevant medical records;</del>
16	-	(₽)-	The clinical standards of the plan;
17	-	<del>(E)</del>	The information provided;
18	-	<del>(F)</del>	The attending physician's recommendations; and
19	-	<del>(G)</del> -	Generally accepted practice guidelines.
20	<del>The-c</del> e	əmmiş	sioner, upon a majority vote of the panel, shall
21	.issue an oi	<del>der</del>	affirming, modifying, or reversing the decision
22	<del>within thir</del>	<del>rty-</del> é	lays of the hearing.



Page 74

### **S.B. NO.** <sup>1274</sup> S.D. 2 H.D. 3 C.D. 1

1	(b) The procedure set forth in this section shall not
2	apply to-claims or allegations of health-provider malpractice,
3	professional negligence, or other professional fault against
4	participating-providers.
5	(c) No-person shall serve on the review panel or in the
6	independent review organization who, through a familial
7	relationship-within the second degree of consanguinity or
8	affinity, or for other reasons, has a direct and substantial
9	professional, financial, or personal interest in:
10	(1) The plan involved in the complaint, including an
11	officer, director, or employee of the plan; or
12	(2) The treatment of the enrollee, including but not
13	limited to the developer or manufacturer of the
14	principal drug, device, procedure, or other therapy at
15	issue.
16	(d) Members-of the review panel-shall-be-granted immunity
17	from liability and damages relating to their duties under this
18	section.
19	(e) An enrollee may be allowed, at the commissioner's
20	discretion, an award of a reasonable sum for attorney's fees and
21	reasonable costs incurred in connection with the external review
22	under this section, unless the commissioner in an administrative
	2011-2273 SB1274 CD1 SMA-3.doc

### **S.B. NO.** <sup>1274</sup> S.D. 2 H.D. 3 C.D. 1

1	proceeding-determines-that-the-appeal-was-unreasonable,
2	fraudulent, excessive, or frivolous.
3	(f) Disclosure of an enrollee's protected health
4	information shall be limited to disclosure for purposes relating
5	to the external review."]
6	SECTION 11. The insurance commissioner shall submit a
7	report to the legislature no later than twenty days prior to the
8	convening of the 2012 regular session on the implementation of
9	this Act including the names of all independent review
10	organizations contracted by the State pursuant to section
11	432E-L, Hawaii Revised Statutes, and data on the number of
12	requests for external review and outcomes of external reviews as
13	maintained by each independent review organization pursuant to
14	section 432E-K(b), Hawaii Revised Statutes.
15	SECTION 12. The insurance commissioner shall assist the
16	department of human services and the Hawaii employer-union
17	health benefits trust fund in compiling data relating to each
18	entity's own administrative review process comparable to that
19	maintained by independent review organizations pursuant to
20	section 432E-K(b), Hawaii Revised Statutes, and submitting a
21	report of the data and findings to the legislature no later than
22	twenty days prior to the convening of the 2012 regular session.
	2011-2273 SB1274 CD1 SMA-3.doc 75

The report submitted pursuant to this section shall include a 1 comparison between outcomes in the review processes maintained 2 by the department of human services and Hawaii employer-union 3 health benefits trust fund, respectively, and outcomes of the 4 review processes of independent review organizations, as well as 5 an analysis of whether or not consumers would have achieved 6 better access to health care services under a review process 7 maintained by an independent review organization. 8

1274 S.D. 2

76

S.B. NO.

9 SECTION 13. If any provision of this Act, or the
10 application thereof to any person or circumstance is held
11 invalid, the invalidity does not affect other provisions or
12 applications of the Act, which can be given effect without the
13 invalid provision or application, and to this end the provisions
14 of this Act are severable.

15 SECTION 14. This Act shall be construed at all times in 16 conformity with the federal Patient Protection and Affordable 17 Care Act, Public Law No. 111-148. If any provision of this part 18 is interpreted to violate the Patient Protection and Affordable 19 Care Act, the commissioner is authorized to adopt by emergency 20 rule-making procedures, any rules as necessary to conform the 21 provisions and procedures of this part with the Patient

22 Protection and Affordable Care Act.

#### **S.B. NO.** <sup>1274</sup> S.D. 2 H.D. 3 C.D. 1

SECTION 15. In codifying the new sections added by section 1 2 of this Act, the revisor of statutes shall substitute 2 appropriate section numbers for the letters used in designating 3 4 the new sections in this Act. 5 SECTION 16. Statutory material to be repealed is bracketed 6 and stricken. New statutory material is underscored. 7 SECTION 17. This Act shall take effect on June 30, 2011; provided that if the United States Department of Health and 8 Human Services by rule or other written guidance extends the 9 time period for the State's existing external review process 10 under section 432E-6, Hawaii Revised Statutes, to any later date 11 12 during 2011, then the effective date of this Act shall be the sooner of the end date of the transition period or January 1, 13 2012; provided further that if the external review requirements 14 15 of the federal Patient Protection and Affordable Care Act of 16 2010 are held unconstitutional by the United States Supreme Court, this Act shall be repealed as of the date that the United 17 States Supreme Court issues its opinion and chapter 432E, Hawaii 18 Revised Statutes, shall be reenacted in the form in which it 19 existed as of the day before the United States Supreme Court 20 21 issued its decision.

#### S.B. NO. <sup>1274</sup> S.D. 2 H.D. 3 C.D. 1

#### Report Title:

Insurance; Health; External Review Procedure

#### Description:

Provides uniform standards for external review procedures based on the National Association of Insurance Commissioners Uniform Health Carrier External Review Model Act, to comply with the requirements of the federal Patient Protection and Affordable Care Act of 2010; requires reports to the legislature. (CD1)

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.

